Fierce Pharma

AUGUST 8, 2024

Following the commercial launch of Bavarian Nordic’s smallpox/mpox vaccine Jynneos earlier this year, the Danish company has locked up yet another supply agreement with the U.S. government. | The Biomedical Advanced Research and Development Authority (BARDA) is handing Bavarian Nordic $156.8 million to “partly replenish” Jynneos vaccine stocks in response to the 2022 outbreak of mpox, the disease formerly known as monkeypox.

Government 344

Government 344

MedCity News

AUGUST 8, 2024

This potential for self-management can reduce the burden on the healthcare system, resulting in fewer doctor visits, lower hospitalization risks, and fewer diagnostic tests as patients can take corrective action earlier or identify issues sooner. The post Wearable Tech is Empowering Patients To Be Proactive in Their Health appeared first on MedCity News.

Patients 130

Patients Doctors Healthcare Healthcare 130

Fierce Pharma

AUGUST 8, 2024

While a glut of drugmakers have raised their 2024 financial guidance after the second quarter, those upgraded sales expectations pale in comparison to Eli Lilly’s new forecast for the year. | Lilly, which reported a 36% sales increase year-over-year to $11.3 billion in the second quarter, is raising its guidance for the full year by a staggering $3 billion.

Sales 276

Sales 276

MedCity News

AUGUST 8, 2024

More than 700 hospitals across the rural U.S. are at risk of closing due to their financial woes — and for more than half of these hospitals, the risk of closure is immediate, according to a new report. The report argued this is due largely to inadequate reimbursement from health plans. The post Why More Than 30% of Rural Hospitals Are at Risk of Closure appeared first on MedCity News.

Healthcare 131

Healthcare Healthcare 131

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Fierce Pharma

AUGUST 8, 2024

After taking a market share lead in the crowded Humira biosimilar space and with other key launches in the works, Novartis spinout Sandoz is raising its full-year sales guidance. | The company touts leading biosimilar market share for its version of AbbVie's Humira.

Sales 270

Sales Leads Marketing 270

Pharmaceutical Commerce

AUGUST 8, 2024

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

Pharma 105

Pharma 105

MedCity News

AUGUST 8, 2024

Through a new partnership with FarmboxRx, Blue Cross Blue Shield of Tennessee members will receive healthy food deliveries after they complete preventive health screenings, like a diabetic eye exam. The post Blue Cross Blue Shield of Tennessee Taps FarmboxRx for Food as Medicine Initiative appeared first on MedCity News.

Food 100

Food Medicine 100

Fierce Pharma

AUGUST 8, 2024

While Apellis Pharmaceuticals has spent much of the year working around setbacks that derailed the ongoing launch of its geographic atrophy (GA) drug Syfovre, a major phase 3 triumph could open up | Empaveli showed strong efficacy in two rare kidney diseases. The result “exceeded our already high expectations," an Apellis exec said, and it led analysts at Evercore ISI to assign the drug a majority future market share against Novartis’ rival.

Pharmaceutical 229

Pharmaceutical Marketing 229

Pharmaceutical Technology

AUGUST 8, 2024

Coming in response to a rise in teenage overdoses across the US, the Purdue auto-injector device is designed to be used by anyone.

105

105

Fierce Pharma

AUGUST 8, 2024

A year after it was hit with a rejection from the FDA, Citius Pharmaceuticals has scored an approval for Lymphir to treat cutaneous T-Cell Lymphoma.

FDA 248

FDA Pharmaceutical 248

Advertisement

Pharmaceutical Commerce

AUGUST 8, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Distribution 104

Distribution Biopharma Pharma Marketing 104

Fierce Pharma

AUGUST 8, 2024

Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. | Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. Eisai inked a molecular glue degrader deal with BeyondSpring that could be worth up to $1.5 billion.

Pharma 130

Pharma 130

pharmaphorum

AUGUST 8, 2024

Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million

Pharma 106

Pharma 106

Pharmaceutical Technology

AUGUST 8, 2024

Novartis has secured US Food and Drug Administration (FDA) accelerated approval for Fabhalta (iptacopan) to treat igAN.

Food and Drug Administration 105

Food and Drug Administration FDA Food 105

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales

PharmaTimes

AUGUST 8, 2024

The study predicted the development of conditions including Alzheimer’s and heart disease

119

119

Pharmaceutical Technology

AUGUST 8, 2024

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals' CREXONT extended-release capsules for PD.

Food and Drug Administration 98

Food and Drug Administration FDA Food Pharmaceutical 98

MedCity News

AUGUST 8, 2024

Addressing America’s maternal health crisis will be complicated and nuanced. Here are a few possible solutions. The post Rural America’s Maternity Crisis: How Locum Tenens Can Help Fill Gaps in Rural Hospitals’ Labor and Delivery Services appeared first on MedCity News.

Healthcare 85

Healthcare Healthcare 85

Pharmaceutical Technology

AUGUST 8, 2024

Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.

105

105

Advertisement

Distribution

pharmaphorum

AUGUST 8, 2024

Roche is said to be considering a sale of cancer data specialist Flatiron Health, just a few years after it bought the company for $1.

Sales 99

Sales 99

Pharmaceutical Technology

AUGUST 8, 2024

The contract will see bulk product for Jynneos replenished and additional services for dose storage.

96

96

pharmaphorum

AUGUST 8, 2024

Novartis gets FDA accelerated approval for Fabhalta in IgA nephropathy as it charts a course to blockbuster sales for the drug

FDA 101

FDA Sales 101

PharmaTech

AUGUST 8, 2024

The reopening of comments addresses the addition of a warning to consumers that acetaminophen may cause skin irritation characterized by reddening, blisters, and rashes.

FDA 69

FDA 69

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

AUGUST 8, 2024

NICE backs Vertex's gene-editing therapy Casgevy as a treatment for beta thalassaemia, a few months after turning it down for sickle cell disease

87

87

Pharmaceutical Commerce

AUGUST 8, 2024

Will the looming changes address the concerns of the patient assistance community?

Patients 98

Patients 98

PharmaVoice

AUGUST 8, 2024

The top drugs at each of the world’s most valuable pharma companies tell the story of just how much the industry has changed over the course of a few years.

Marketing 64

Marketing Pharma 64

Clarivate

AUGUST 8, 2024

Data might be the most valuable commodity on earth. When analyzed correctly, it can help businesses understand patterns and trends, opportunities and risks, standards and benchmarks. However, like any commodity, raw data alone has its limitations. When it comes to intellectual property (IP), the true value emerges when data is enriched. Enriched data improves search efficiency, saves time by quickly identifying relevant documents, provides clear and standardized abstracts, offers comprehensive g

Competition 59

Competition Consulting Distribution Marketing 59

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

PharmaTimes

AUGUST 8, 2024

Lung cancer accounts for an estimated two million global diagnoses and 1.

91

91

Pharmaceutical Technology

AUGUST 8, 2024

The gene editing therapy will now be accessible to NHS England patients with beta-thalassemia, potentially replacing lifelong transfusions.

Patients 64

Patients 64

European Pharmaceutical Review

AUGUST 8, 2024

An investigational, individualised neoantigen therapy, with personalised encoded mRNA, has demonstrated potential to enable patient’s immune system to target cells that cause cancer. Researchers from the related study highlighted that it has been challenging to develop engineering therapies that give the immune system enough training to identify a patient’s neoantigens.

Engineering 52

Engineering Patients Training Pharmaceutical 52

PharmaVoice

AUGUST 8, 2024

Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

52

52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety